Newly acquired Alexion pays $100M for Rhythm's speedy review voucher

Just a few weeks after being snapped up by AstraZeneca, rare disease specialist Alexion has nabbed a priority review voucher from Rhythm that can speed up the approval of one of its late-stage meds.

Initially, we didn’t know who had snapped up that voucher from Rhythm when it first announced the sale yesterday, but in a Securities and Exchange Commission filing today, Alexion, in the midst of a $39 billion buyout from AstraZeneca, was named as the new owner.